These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 12393624

  • 1. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
    Roesler J, Brenner S, Bukovsky AA, Whiting-Theobald N, Dull T, Kelly M, Civin CI, Malech HL.
    Blood; 2002 Dec 15; 100(13):4381-90. PubMed ID: 12393624
    [Abstract] [Full Text] [Related]

  • 2. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.
    Naumann N, De Ravin SS, Choi U, Moayeri M, Whiting-Theobald N, Linton GF, Ikeda Y, Malech HL.
    Gene Ther; 2007 Nov 15; 14(21):1513-24. PubMed ID: 17728796
    [Abstract] [Full Text] [Related]

  • 3. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.
    Brenner S, Whiting-Theobald NL, Linton GF, Holmes KL, Anderson-Cohen M, Kelly PF, Vanin EF, Pilon AM, Bodine DM, Horwitz ME, Malech HL.
    Blood; 2003 Oct 15; 102(8):2789-97. PubMed ID: 12829597
    [Abstract] [Full Text] [Related]

  • 4. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.
    Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M.
    Hum Gene Ther; 1998 Jul 20; 9(11):1561-70. PubMed ID: 9694155
    [Abstract] [Full Text] [Related]

  • 5. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
    Dinauer MC, Li LL, Björgvinsdóttir H, Ding C, Pech N.
    Blood; 1999 Aug 01; 94(3):914-22. PubMed ID: 10419882
    [Abstract] [Full Text] [Related]

  • 6. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
    Nunoi H, Ishibashi F.
    Hum Cell; 1999 Sep 01; 12(3):103-8. PubMed ID: 10695016
    [Abstract] [Full Text] [Related]

  • 7. Gene therapy of chronic granulomatous disease.
    Grez M, Becker S, Saulnier S, Knöss H, Ott MG, Maurer A, Dinauer MC, Hoelzer D, Seger R, Hossle JP.
    Bone Marrow Transplant; 2000 May 01; 25 Suppl 2():S99-104. PubMed ID: 10933200
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lentivirus-mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells.
    Saulnier SO, Steinhoff D, Dinauer MC, Zufferey R, Trono D, Seger RA, Hossle JP.
    J Gene Med; 2000 May 01; 2(5):317-25. PubMed ID: 11045425
    [Abstract] [Full Text] [Related]

  • 13. NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes.
    Geiszt M, Lekstrom K, Brenner S, Hewitt SM, Dana R, Malech HL, Leto TL.
    J Immunol; 2003 Jul 01; 171(1):299-306. PubMed ID: 12817011
    [Abstract] [Full Text] [Related]

  • 14. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker.
    Sadat MA, Pech N, Saulnier S, Leroy BA, Hossle JP, Grez M, Dinauer MC.
    Hum Gene Ther; 2003 May 01; 14(7):651-66. PubMed ID: 12804147
    [Abstract] [Full Text] [Related]

  • 15. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
    Brendel C, Rothe M, Santilli G, Charrier S, Stein S, Kunkel H, Abriss D, Müller-Kuller U, Gaspar B, Modlich U, Galy A, Schambach A, Thrasher AJ, Grez M.
    Hum Gene Ther Clin Dev; 2018 Jun 01; 29(2):69-79. PubMed ID: 29664709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.
    Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, Dowey SN, Cheng L, Malech HL.
    Blood; 2011 May 26; 117(21):5561-72. PubMed ID: 21411759
    [Abstract] [Full Text] [Related]

  • 18. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
    Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, Bueren JA, Grez M, Thrasher AJ.
    Mol Ther; 2011 Jan 26; 19(1):122-32. PubMed ID: 20978475
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.